MindMaze Therapeutics AGM: New Board Members Elected, Capital Increase Rejected

MindMaze Therapeutics Holding SA (SIX: MMTX), a global leader in scalable precision neurotherapeutics, announced the results of its Annual General Meeting (AGM) held on June 25, 2026, in Geneva, Switzerland. Shareholders approved all proposals submitted by the Board of Directors, except the proposed increase in conditional share capital, which failed to achieve the required qualified majority. Key outcomes included the re-election of Walid Hanna, Olaf Blanke, and Martin Reiss to the Board, and the election of Brad Hollinger, Founder, Chairman, and CEO of Vibra Healthcare, and Zach Henderson, CEO of MindMaze Therapeutics, as new members. Additionally, shareholders approved the 2025 Annual Report and financial statements, the appropriation of available earnings, the discharge of the Board and Executive Committee, and the re-election of Walid Hanna as Chairman. The AGM also approved compensation proposals and the consultative vote on the 2025 Compensation Report. Detailed voting results will be published on the Company’s website. For further details, the AGM Invitation provides comprehensive information.

MindMaze Therapeutics (MMTX) is dedicated to redefining recovery for patients with neurological disorders through its innovative platform that integrates advanced software, proprietary sensors, and AI-driven data analytics. The company’s FDA-cleared and CE-marked products aim to address the systemic shortage of specialized clinicians by offering scalable, reimbursable solutions for conditions like stroke and Parkinson’s disease. With rigorous clinical validation and a robust R&D pipeline, MindMaze is operationalizing the future of neurorestorative medicine. The new board members bring valuable expertise: Brad Hollinger from Vibra Healthcare and Zach Henderson as CEO are expected to guide the company’s strategic direction. The rejection of the conditional share capital increase indicates shareholder caution regarding dilution, but overall approval of other proposals signals confidence in the company’s management and direction.

This AGM outcome is pivotal for MindMaze as it continues to expand its presence in the neurotherapeutics market. The company’s focus on scalable precision treatments could transform care for millions suffering from neurological conditions, making this news relevant to patients, healthcare providers, and investors alike. The election of new board members with deep industry experience may accelerate MindMaze’s mission to bridge the gap in clinician availability through technology-driven solutions. As the company moves forward, its ability to secure shareholder support for future capital initiatives will be crucial for funding R&D and commercialization efforts.